November 15, 2019 / 10:37 PM / a month ago

BeiGene prices lymphoma drug at $12,935 for a 30-day supply

(Reuters) - China-based drugmaker BeiGene Ltd on Friday priced its drug, Brukinsa, to treat a rare form of lymphoma at $12,935 for a 30-day supply.

The U.S. Food and Drug Administration on Thursday approved the drug, giving a boost to the company’s strategy of largely using data from studies held outside the United States.

Brokerage Cowen & Co expects peak global sales of Brukinsa to be $836 million across all indications, and $90 million in mantle cell lymphoma.

Reporting by Trisha Roy in Bengaluru; Editing by Amy Caren Daniel

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below